OKLAHOMA CITY, March 11, 2023 — Cytovance Biologics and Phenotypeca Limited (Phenotypeca), a research and development organization with proprietary yeast expression technology that provides key advantages in recombinant protein manufacture, have entered into an agreement to provide optimized Saccharomyces cerevisiae strains for biopharmaceutical manufacturing.
OKLAHOMA CITY, January 16, 2023 — Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics, announces the appointment of Mr. Ping Zhang as Chief Executive Officer.
Any current Good Manufacturing Practice (cGMP) E.coli program must be based on a solid strain development strategy. This thought led to the development of Cytovance’s Keystone Expression System to provide a robust, high-yield E.coli strain to support cGMP manufacturing of a biologic.
The number and variety of protein therapeutics have increased dramatically in recent years. To satisfy therapeutic demand, these molecules must be produced at large scale in mammalian or bacterial cell hosts; but with the greater variety in protein therapeutic molecules
Process Characterization & Statistical Modeling — Transforming Data into Knowledge Throughout the Product Lifecycle, Upcoming Webinar Hosted by Xtalks. It’s no surprise that data plays a pivotal role in the biopharmaceutical industry.
Cytovance Biologics and Avantor Collaborate to Accelerate Plasmid DNA Development for Global Biopharma Market. Cytovance Biologics and Avantor will accelerate plasmid production and sourcing services for new and existing viral vector and mRNA-based vaccine and therapeutic customers.
Cytovance Biologics, a global leading contract development and manufacturing provider of microbial, mammalian and plasmid DNA services in clinical and commercial manufacturing will participate in the upcoming BIO International Convention 2022 in San Diego
Cytovance Biologics announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process. The webinar set for June 24, 2021 at 12pm EDT will feature a discussion on strain selection
Cytovance® Biologics announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process. The webinar set for June 24, 2021 at 12pm EDT will feature a discussion on strain selection, plasmid optimization, media composition.
Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene therapy biologics, announces its first webinar of the 2021 series: Regulatory Strategies for Gene Therapy Product Development.